Aclaris Therapeutics (ACRS) Assets Average (2015 - 2026)

Aclaris Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $179.6 million for Q1 2026.

• In Q1 2026, Assets Average fell 14.16% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $179.6 million (down 14.16% YoY), while the FY2025 annual figure was $190.4 million, down 8.84% from the prior year.
• Assets Average was $179.6 million for Q1 2026 at Aclaris Therapeutics, up from $168.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $272.8 million in Q3 2022 to a low of $167.6 million in Q2 2024.
• Historically, Assets Average has averaged $211.4 million across 5 years, with a median of $207.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Assets Average jumped 105.76% in 2022, then decreased 27.98% in 2024.
• A 5-year view of Assets Average shows it stood at $261.1 million in 2022, then slipped by 20.39% to $207.9 million in 2023, then declined by 3.14% to $201.4 million in 2024, then dropped by 16.57% to $168.0 million in 2025, then increased by 6.9% to $179.6 million in 2026.
• The last three Assets Average figures came in at $179.6 million (Q1 2026), $168.0 million (Q4 2025), and $182.3 million (Q3 2025), per Business Quant data.